Net Profit Margin: 22.77%
Is the net profit margin high or low?
The net profit margin of 22.77% is in line with its 5-year average of 21.68%, near the low end of its 5-year range (-0.72%–138.22%).
As of Saturday, June 27, 2026. 21.92% above its 12-month average of 18.68%.
GSK Profit Margin
Reported quarterly profit margin; no daily interpolation.
GSK Average Net Profit Margin Chart
GSK Current vs Average Net Profit Margin Chart
GSK Net Profit Margin Metrics
NET PROFIT MARGIN
22.77%
NET PROFIT MARGIN AVG TTM
18.68%
NET PROFIT MARGIN AVG 3Y
14.86%
NET PROFIT MARGIN AVG 5Y
15.85%
NET PROFIT MARGIN AVG 10Y
12.96%
NET PROFIT MARGIN AVG 15Y
13.53%
NET PROFIT MARGIN AVG 20Y
15.87%
CURRENT VS TTM AVG
+21.92%
CURRENT VS 3Y AVG
+53.19%
CURRENT VS 5Y AVG
+43.63%
CURRENT VS 10Y AVG
+75.70%
CURRENT VS 15Y AVG
+68.32%
CURRENT VS 20Y AVG
+43.45%
GSK Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 22.77% | 18.68% | 14.86% | 15.85% |
| Medtronic plc (MDT)vs › | $103.66B | 13.20% | 13.55% | 12.62% | 13.06% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 15.01% | -1.95% | 6.91% | 3.59% |
| McKesson Corporation (MCK)vs › | $89.39B | 1.18% | 1.05% | 1.09% | 0.48% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 8.89% | 8.57% | 8.64% | 8.95% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 2.62% | 3.11% | 3.37% | 3.60% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 35.40% | 13.94% | 25.44% | 29.40% |
| Stryker Corporation (SYK)vs › | $127.39B | 13.21% | 13.09% | 13.60% | 12.87% |
| CVS Health Corp. (CVS)vs › | $133.13B | 0.72% | 0.84% | 1.34% | 1.79% |
| Cigna Corporation (CI)vs › | $74.81B | 2.26% | 1.78% | 2.48% | 3.04% |
Margin Comparison
Operating Margin
25.6%
Net Profit Margin
22.8%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for GSK plc (GSK)?
- The net profit margin for GSK stock is 22.77%.
- Is GSK plc's net profit margin high or low?
- The net profit margin of 22.77% is in line with its 5-year average of 21.68%, near the low end of its 5-year range (-0.72%–138.22%).
- What is the TTM average net profit margin for GSK plc (GSK)?
- The TTM average net profit margin for GSK stock is 18.68%.
- What is the 3Y average net profit margin for GSK plc (GSK)?
- The 3Y average net profit margin for GSK stock is 14.86%.
- What is the 5Y average net profit margin for GSK plc (GSK)?
- The 5Y average net profit margin for GSK stock is 15.85%.
- What is the 10Y average net profit margin for GSK plc (GSK)?
- The 10Y average net profit margin for GSK stock is 12.96%.
- What is the 15Y average net profit margin for GSK plc (GSK)?
- The 15Y average net profit margin for GSK stock is 13.53%.
- What is the 20Y average net profit margin for GSK plc (GSK)?
- The 20Y average net profit margin for GSK stock is 15.87%.
GSK Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 22.77% |
| 2025-12-31 | 7.38% |
| 2025-09-30 | 23.55% |
| 2025-06-30 | 18.07% |
| 2025-03-31 | 21.61% |
| 2024-12-31 | 5.10% |
| 2024-09-30 | -0.72% |
| 2024-06-30 | 14.88% |
| 2024-03-31 | 14.21% |
| 2023-12-31 | 4.35% |
| 2023-09-30 | 17.97% |
| 2023-06-30 | 22.62% |
| 2023-03-31 | 21.44% |
| 2022-12-31 | 19.81% |
| 2022-09-30 | 138.22% |
| 2022-06-30 | 12.09% |
| 2022-03-31 | 25.06% |
| 2021-12-31 | 7.86% |
| 2021-09-30 | 20.64% |
| 2021-06-30 | 23.90% |
| 2021-03-31 | 14.46% |
| 2020-12-31 | 7.75% |
| 2020-09-30 | 14.39% |
| 2020-06-30 | 29.68% |
| 2020-03-31 | 17.22% |
| 2019-12-31 | 14.60% |
| 2019-09-30 | 16.54% |
| 2019-06-30 | 12.34% |
| 2019-03-31 | 10.83% |
| 2018-12-31 | 14.82% |
| 2018-09-30 | 17.52% |
| 2018-06-30 | 6.03% |
| 2018-03-31 | 7.60% |
| 2017-12-31 | -7.15% |
| 2017-09-30 | 15.45% |
| 2017-06-30 | -2.46% |
| 2017-03-31 | 14.17% |
| 2016-12-31 | 3.39% |
| 2016-09-30 | 10.71% |
| 2016-06-30 | -6.66% |
| 2016-03-31 | 4.53% |
| 2015-12-31 | -5.63% |
| 2015-09-30 | 8.78% |
| 2015-06-30 | 2.53% |
| 2015-03-31 | 143.88% |
| 2014-12-31 | 16.70% |
| 2014-09-30 | 7.10% |
| 2014-06-30 | 11.76% |
| 2014-03-31 | 11.90% |
| 2013-12-31 | 35.64% |
| 2013-09-30 | 14.88% |
| 2013-06-30 | 15.79% |
| 2013-03-31 | 14.85% |
| 2012-12-31 | 12.70% |
| 2012-09-30 | 16.93% |
| 2012-06-30 | 19.16% |
| 2012-03-31 | 19.70% |
| 2011-12-31 | 17.94% |
| 2011-09-30 | 19.40% |
| 2011-06-30 | 16.46% |
| 2011-03-31 | 23.16% |
| 2010-12-31 | -9.59% |
| 2010-09-30 | 18.91% |
| 2010-06-30 | -4.33% |
| 2010-03-31 | 18.21% |
| 2009-12-31 | 20.14% |
| 2009-09-30 | 19.75% |
| 2009-06-30 | 21.27% |
| 2009-03-31 | 16.71% |
| 2008-12-31 | 14.72% |
| 2008-09-30 | 17.46% |
| 2008-06-30 | 21.89% |
| 2008-03-31 | 22.99% |
| 2007-12-31 | 17.71% |
| 2007-09-30 | 23.93% |
| 2007-06-30 | 23.49% |
| 2007-03-31 | 27.07% |
| 2006-12-31 | 19.82% |
| 2006-09-30 | 24.65% |
| 2006-06-30 | 22.63% |
| 2006-03-31 | 25.84% |
| 2005-12-31 | 18.99% |
| 2005-09-30 | 22.06% |
| 2005-06-30 | 22.67% |
| 2005-03-31 | 23.87% |
| 2004-12-31 | 21.63% |
| 2004-09-30 | 20.47% |
| 2004-06-30 | 21.91% |
| 2004-03-31 | 21.36% |
| 2003-12-31 | 14.62% |
| 2003-09-30 | 21.30% |
| 2003-06-30 | 24.84% |
| 2003-03-31 | 22.94% |
| 2002-12-31 | 16.58% |
| 2002-09-30 | 15.74% |
| 2002-06-30 | 21.77% |
Related Metrics
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels